ValuEngine downgraded shares of Blueprint Medicines (NASDAQ:BPMC) from a hold rating to a sell rating in a research report released on Friday morning.

BPMC has been the topic of several other reports. Zacks Investment Research downgraded Blueprint Medicines from a hold rating to a sell rating in a research report on Thursday, November 2nd. Canaccord Genuity restated a buy rating and issued a $56.00 price objective on shares of Blueprint Medicines in a research report on Monday, September 11th. Wedbush restated an outperform rating and issued a $82.00 price objective (up from $70.00) on shares of Blueprint Medicines in a research report on Monday, November 6th. DA Davidson began coverage on Blueprint Medicines in a research report on Friday, September 29th. They set a buy rating and a $90.00 target price on the stock. Finally, BidaskClub downgraded Blueprint Medicines from a strong-buy rating to a buy rating in a research report on Saturday, August 19th. Two investment analysts have rated the stock with a sell rating and ten have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $70.47.

Shares of Blueprint Medicines (NASDAQ:BPMC) traded down $2.24 during trading hours on Friday, hitting $72.82. The stock had a trading volume of 369,279 shares, compared to its average volume of 383,940. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a twelve month low of $25.08 and a twelve month high of $77.91.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The company had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. During the same quarter in the prior year, the company earned ($0.62) earnings per share. The firm’s revenue was up 31.0% compared to the same quarter last year. equities analysts anticipate that Blueprint Medicines will post -3.76 EPS for the current fiscal year.

In other news, insider Anthony L. Boral sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $70.40, for a total value of $352,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jeffrey W. Albers sold 30,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $70.31, for a total value of $2,109,300.00. The disclosure for this sale can be found here. Insiders have sold 72,639 shares of company stock worth $4,871,743 over the last quarter. 3.40% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Blueprint Medicines by 10.8% in the 2nd quarter. FMR LLC now owns 5,300,589 shares of the biotechnology company’s stock worth $268,581,000 after purchasing an additional 516,835 shares during the period. BlackRock Inc. raised its holdings in shares of Blueprint Medicines by 39.6% in the 2nd quarter. BlackRock Inc. now owns 2,864,255 shares of the biotechnology company’s stock worth $145,131,000 after purchasing an additional 811,820 shares during the period. Lord Abbett & CO. LLC raised its holdings in shares of Blueprint Medicines by 0.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 1,729,169 shares of the biotechnology company’s stock worth $87,617,000 after purchasing an additional 8,903 shares during the period. Vanguard Group Inc. raised its holdings in shares of Blueprint Medicines by 16.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock worth $71,746,000 after purchasing an additional 195,517 shares during the period. Finally, State Street Corp raised its holdings in shares of Blueprint Medicines by 76.8% in the 2nd quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock worth $70,936,000 after purchasing an additional 608,296 shares during the period. Institutional investors own 91.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/02/blueprint-medicines-bpmc-downgraded-by-valuengine-to-sell.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Stock Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related stocks with our FREE daily email newsletter.